NCT04628988 is a Phase 1 clinical trial of CC-90011 in Prostatic Neoplasms, sponsored by Celgene.

Who is sponsoring NCT04628988?

NCT04628988 is sponsored by Celgene.

What drugs are being tested in NCT04628988?

Interventions in NCT04628988: CC-90011, Abiraterone, Prednisone.

What condition does NCT04628988 study?

NCT04628988 studies Prostatic Neoplasms.

Is NCT04628988 still recruiting?

NCT04628988 is currently completed. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT04628988

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Completed Phase 1 Last updated 13 September 2023

What this trial tests

Phase 1 trial testing CC-90011 in Prostatic Neoplasms in 6 participants. Completed in 26 May 2023.

Timeline

28 July 2021

Primary endpoint
26 May 2023

26 May 2023

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	28 July 2021
Primary completion	26 May 2023
Estimated completion	26 May 2023
Sites	1 location across United States

Drugs / interventions tested

CC-90011 — full drug profile →
Abiraterone (ABIRATERONE) — full drug profile →
Prednisone (prednisone) — full drug profile →

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →

Sponsor

Celgene — full company profile →

Who can join

18 and older, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, positron emission tomography (PET) imaging Proof of Biology (POB) study to determine whether CC -90011 reverses, by the induction of androgen receptor (AR) expression, the castration resistance, due to lineage switch, in participants with mCRPC that have failed enzalutamide as last prior therapy. This study aims to assess whether CC-90011 can induce AR expression and, consequently, re-sensitize tumors to anti-hormonal therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
Targeting epigenetic regulators to overcome drug resistance in cancers.
Wang N, Ma T, Yu B, Yu B. · · 2023 · cited 213× · PMID 36797239 · DOI 10.1038/s41392-023-01341-7
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.
He Y, Xu W, Xiao YT, Huang H, et al · · 2022 · cited 192× · PMID 35750683 · DOI 10.1038/s41392-022-01042-7
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
Noce B, Di Bello E, Fioravanti R, Mai A. · · 2023 · cited 78× · PMID 36817147 · DOI 10.3389/fphar.2023.1120911
Pharmacological targeting of the cancer epigenome.
Mabe NW, Perry JA, Malone CF, Stegmaier K. · · 2024 · cited 36× · PMID 38937652 · DOI 10.1038/s43018-024-00777-2
Biological and therapeutic role of LSD1 in Alzheimer's diseases.
Li Y, Zhao Y, Li X, Zhai L, et al · · 2022 · cited 12× · PMID 36386192 · DOI 10.3389/fphar.2022.1020556
Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.
Zamora I, Freeman MR, Encío IJ, Rotinen M. · · 2023 · cited 10× · PMID 37761978 · DOI 10.3390/ijms241813673

Verify or expand the search:

Other trials of CC-90011

Trials testing the same drug.

NCT04748848 — A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R · Phase 1 · terminated
NCT04350463 — A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers · Phase 2 · completed
NCT03850067 — A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide · Phase 1 · completed
NCT02875223 — A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's L · Phase 1 · terminated

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04628988 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04628988.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing